Akademik Veri Yönetim Sistemi
ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, cilt.16, sa.6, ss.397-400, 2025 (ESCI)
Aim: As a result of the developments in breast cancer treatment, the life expectancy of patients has been extended. This fact has brought the morbidity of breast cancer surgery to the fore. Axillary dissection is the major factor responsible for morbidity. In the present study, we aimed to determine the safety of sentinel node biopsy in patients without pathological lymph node involvement using breast MRI taken after neoadjuvant chemotherapy. Material and Methods: The study was carried out in the General Surgery Department of Bagcilar Training and Research Hospital between 15.02.2021 and 15.07.2021 on patients planned to undergo surgery after neoadjuvant chemotherapy. Postoperative axillary pathology findings were compared with patients without pathological axillary lymphadenopathy in breast MRI results after neoadjuvant chemotherapy. Results: Ninety patients were operated. After the treatment, 57 of them became cN0 on breast MRI. When >= 3 negative SLNB was removed in the group of patients who were cN0 after the treatment, no pathological lymph involvement was observed in the axilla. Discussion: The gold standard for evaluating chemotherapy efficacy is pathologic assessment, the residual cancer burden score (RCB) and the Miller-Payne score are used for this purpose. However, these evaluations are not practical since they need the patient to undergo surgery. For this reason, imaging methods such as mammography, US, MRI and PET-CT are used in the follow-up of NACT treatment response. WHO criteria and RECIST are used to standardize treatment response values with imaging methods.